Implication of normal liver enzymes in liver disease
Vincenza Calvaruso,
Antonio Craxì,
Vincenza Calvaruso
Gastroenterologia & Epatologia, DIBIMIS, Università di Palermo, Italy
Search for more papers by this authorAntonio Craxì
Gastroenterologia & Epatologia, DIBIMIS, Università di Palermo, Italy
Search for more papers by this authorVincenza Calvaruso,
Antonio Craxì,
Vincenza Calvaruso
Gastroenterologia & Epatologia, DIBIMIS, Università di Palermo, Italy
Search for more papers by this authorAntonio Craxì
Gastroenterologia & Epatologia, DIBIMIS, Università di Palermo, Italy
Search for more papers by this authorVincenza Calvaruso, Gastroenterologia & Epatologia, DIBIMIS, University of Palermo, Piazza delle Cliniche n.2, 90127 Palermo, Italy. E-mail: [email protected]
Abstract
Summary. Chronic liver disease is usually asymptomatic until its late stages and also significant hepatic necroinflammation and fibrosis may be present in persistently normal ALT levels HBV, HCV carriers or similarly, in patients with nonalcoholic fatty liver disease. Given the large number of persons in the general population which may harbor a clinically significant liver disease behind the screen of normal alanine aminotransferase, more attention should be devoted to future research for alternative noninvasive markers of liver damage.
References
- 1 Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997; 3(Suppl 1): 15S–20S.
- 2 Okanoue T, Makiyama A, Nakayama M et al. A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. J Hepatol 2005; 43(4): 599–605.
- 3 Lai CL, Yuen MF. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med 2007; 147(1): 58–61.
- 4 Dufour DR, Lott JA, Nolte FS et al. Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Clin Chem 2000; 46: 2027–2049.
- 5 Puoti C, Castellacci R, Montagnese F et al. Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC). J Hepatol 2002; 37: 117–123.
- 6 Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology 1997; 26: 133S–136S.
- 7 Shindo M, Arai K, Sokawa Y et al. The virological and histological states of anti-hepatitis C virus-positive subjects with normal liver biochemical values. Hepatology 1995; 22: 418–425.
- 8 Rumi MG, De Filippi F, La Vecchia C et al. Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients. Gut 2005; 54(3): 402–406.
- 9 Esteban JI, Lopez-Talavera JC, Genesca J et al. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. Ann Intern Med 1991; 115: 443–449.
- 10 Mathurin P, Moussalli J, Cadranel JF et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998; 27: 868–872.
- 11 Prati D, Taioli E, Zanella A et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1–10.
- 12 Pradat P, Alberti A, Poynard T et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology 2002; 36(pt 1): 973–977.
- 13 Shiffman ML, Diago M, Tran A et al. Chronic hepatitis C in patients with persistently normal alanine transaminaselevels. Clin Gastroenterol Hepatol 2006; 4: 645–652.
- 14 Hui CK, Belaye T, Montegrande K, Wright TL. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminases. J Hepatol 2003; 38: 511–517.
- 15 Alberti A, Noventa F, Benvegnù L et al. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med 2002; 137(12): 961–964.
- 16 Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of Hepatitis C. Hepatology 2004; 39: 1147.
- 17 Colletta C, Smirne C, Fabris C et al. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology 2005; 42: 838–845.
- 18 Poynard T, Munteanu M, Ngo Y et al. Diagnostic value of FibroTest with normal serum aminotransferases. Hepatology 2006; 43: 374–375.
- 19 Koda M, Matunaga Y, Kawakami M et al. FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007; 45: 297–306.
- 20 Fabris C, Smirne C, Toniutto P et al. Assessment of liverfibrosis progression in patients with chronic hepatitis C andnormal alanine aminotransferase values: the role of AST to the platelet ratio index. Clin Biochem 2006; 39: 339–343.
- 21 Sebastiani G, Vario A, Guido M et al. Stepwise combination algorithms of noninvasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006; 44: 686–693.
- 22 Sebastiani G, Vario A, Guido M, Alberti A. Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases. J Viral Hepat 2008; 15: 212–218.
- 23 Maida I, Soriano V, Barreiro P et al. Liver fibrosis stage and HCV genotype distribution in HIV-HCV coinfected patients with persistently normal transaminases. AIDS Res Hum Retroviruses 2007; 23(6): 801–804.
- 24 Sandrin L, Tanter M, Gennisson JL et al. Shear elasticity probe for soft tissues with 1-D transient elastography. IEEE Trans Ultrason Ferroelectr Freq Control 2002; 49: 436–446.
- 25 Coco B, Oliveri F, Maina AM et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 2007; 14(5): 360–369.
- 26 Arena U, Vizzutti F, Corti G et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology 2008; 47: 380–384.
- 27 Sagir A, Erhardt A, Schmitt M, Haussinger D. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology 2008; 47: 592–597.
- 28 Calvaruso V, Cammà C, Di Marco V et al. Error factors for transient elastography in chronic Hepatitis C. Hepatology 2008; 48: 65A.
- 29 Prieto M, Olaso V, Verdu C et al. Does the healthy hepatitis C virus carrier state really exist? An analysis using polymerase chain reaction. Hepatology 1995; 22: 413–417.
- 30 Shakil AO, Conry-Cantilena C, Alter HJ et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med 1995; 123: 330–337.
- 31 Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 2002; 36: S179–S184.
- 32 EASL International Consensus Conference on Hepatitis C. EASL International Consensus Conference on Hepatitis C: Consensus Statement. J Hepatol 1999; 30: 956–961.
- 33 Puoti C, Guido M, Mangia A et al. (Committee on HCV carriers with normal alanine aminotransferase levels of the Italian Association for The Study of the Liver). Clinical management of HCV carriers with normal aminotransferase levels. Dig Liver Dis 2003; 35: 362–369.
- 34 Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology 1997; 26(Suppl 1): 133S–136S.
- 35 Zeuzem S, Diago M, Gane E et al. International, multicenter, randomized, controlled study for the treatment of patients with chronic hepatitis C and persistently normal ALT levels with PegInterferon Alfa-2a (40 Kd) (Pegasys) and Ribavirin (copegus). Hepatology 2003; 38(4): 10635.
- 36 National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002—June 10–12. Hepatology 2002; 36: S3–S20.
- 37 Alberti A. Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels. J Hepatol 2005; 42: 266–274.
- 38 Keeffe EB, Dieterich DT, Han SHB et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4: 936–962.
- 39 Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507–539.
- 40 Hoofnagle JH, Doo E, Liang TJ et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45: 1056–1075.
- 41 Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65–73.
- 42 Iloeje UH, Yang HI, Su J et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678–686.
- 43 Yuen MF, Yuan HJ, Wong DKH et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 2005; 54: 1610–1614.
- 44 Yim HJ, Lok AS-F. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006; 43: S173–S181.
- 45 Hui C-K, Leung N, Yuen S-T et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immunetolerant phase. Hepatology 2007; 46: 395–401.
- 46 Nguyen MH, Trinh H, Garcia RT et al. Significant histologic disease in HBV-infected patients with normal to minimally elevated ALT levels at initial evaluation (abstract). Hepatology 2005; 42: 593A.
- 47 Terrault N, Kim WR, Lim SG et al. Presence of biopsy-proven histologic damage (necroinflammation and fibrosis) is common even when ALT is less than 2x ULN in patients with chronic hepatitis B (CHB) (abstract). Gastroenterology 2007; 132: A729–A730.
- 48 McGill D, Rakela J, Zinsmeister A et al. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 1990; 99: 1396–1400.
- 49 Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495–500.
- 50 Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507–539.
- 51 Lin CL, Liao LY, Liu CJ et al. Hepatitis B viral factors in HbeAg negative carriers with persistently normal serum alanine aminotransferase levels. Hepatology 2007; 45: 1193–1198.
- 52 Lai M, Hyatt B, Afdhal N. Role of liver biopsy in patients with normal ALT and high HBV DNA (abstract). Hepatology 2005; 42: 720A.
- 53 Wang C, Deubner H, Shuhart M et al. High prevalence of significant fibrosis in patients with immunotolerance to chronic hepatitis B infection [Abstract]. Hepatology 2005; 42: 573A.
- 54 Brunetto MR, Oliveri F, Coco B et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36: 263–270.
- 55 Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002; 36: 1408–1415.
- 56 Lebensztejn DM, Kaczmarski M, Sobaniec-Lotowska M et al. Serum laminin-2 and hyaluronan predict severe liver fibrosis in children with chronic hepatitis B. Hepatology 2004; 39: 868–869.
- 57 Hui AY, Chan HL, Wong VW et al. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol 2005; 100: 616–623.
- 58 Myers RP, Tainturier MH, Ratziu V et al. Prediction of liver histologicalle-Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003; 39: 222–230.
- 59 Poynard T, Zoulim F, Ratziu V et al. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol 2005; 100: 1970–1980.
- 60 Sebastiani G, Vario A, Guido M, Alberti A. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 2007; 13(4): 525–531.
- 61 Chan HL-Y, Wong GL-H, Choi PC-L et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat 2009; 16: 36–44.
- 62 Farrell CG, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99–S112.
- 63 Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003; 37: 1202–1219.
- 64 GC Farrell, J George, M Dela, P Hall, AJ McCullough (eds). Fatty Liver Disease: NASH and Related Disorders. Malden, MA: Blackwell Publishing, 2005: 1–319.
- 65 Bellentani S, Saccoccio G, Masatti F et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112–117.
- 66 Chitturi S, Abeygunasekera S, Farrell GC et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373–379.
- 67 Pagano G, Pacini G, Musso G et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002; 35: 367–372.
- 68 Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917–923.
- 69 Sonsuz A, Basaranoglu M, Ozbay G. Relationship between aminotransferase levels and histopathological findings in patients with nonalcoholic steatohepatitis (letter). Am J Gastroenterol 2000; 95: 1370–1371.
- 70 Bacon BR, Farahvash MJ, Janney CG, Neuschwander Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 1103–1109.
- 71 Powell EE, Cooksley WG, Hanson R et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74–80.
- 72 Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387–1395.
- 73 Mofrad P, Contos MJ, Haque M et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37: 1286–1292.
- 74 Matteoni CA, Younossi ZM, Gramlich T et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413–1419.
- 75 Marcos A, Fisher RA, Ham JM et al. Selection and outcome of living donors for adult to adult right lobe transplantation. Transplantation 2000; 69: 2410–2415.
- 76 Minervini MI, Ruppert K, Fontes P et al. Liver biopsy findings from healthy potential living liver donors: Reasons for disqualification, silent diseases and correlation with liver injury tests. J Hepatol 2009; 50(3): 501–510.
- 77 Fracanzani AL, Valenti L, Bugianesi E et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes. Hepatology 2008; 48: 792–798.
- 78 Gaidos JKJ, Hillner BE, Sanyal AJ. A decision analysis study of the value of a liver biopsy in nonalcoholic steatohepatitis. Liver Int 2008; 28: 650–658.
- 79 Sakugawa H, Nakayoshi T, Kobashigawa K et al. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2005; 11: 255–259.
- 80 Lindqvist U, Laurent TC. Serum hyaluronan and aminoterminal propeptide of type III procollagen: variation with age. Scand J Clin Lab Invest 1992; 52: 613–621.
- 81 Ueno T, Inuzuka S, Torimura T et al. Significance of serum type-IV collagen levels in various liver diseases. Measurement with a one-step sandwich enzyme immunoassay using monoclonal antibodies with specificity for pepsin-solubilized type-IV collagen. Scand J Gastroenterol 1992; 27: 513–520.
- 82 Yoneda M, Yoneda M, Mawatari H et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Digest Liver Dis 2008; 40: 371–378.
- 83 Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48: 835–847.
- 84 Karmen A, Wroblewski F, LaDue JS. Transaminase activity in human blood. J Clin Invest 1955; 34: 126–133.
- 85 Kallei L, Hahn A, Roder VZ. Correlation between histological findings and serum transaminase values in chronic diseases of the liver. Acta Med Scand 1964; 175: 49–56.
Citing Literature
